-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
Ebola risk now at highest level in DR Congo, says WHO
The risk from the deadly Ebola outbreak has been raised to the highest level for the Democratic Republic of Congo, the World Health Organization said Friday, as the toll continued to rise.
There are now 82 confirmed cases and seven confirmed deaths in the DR Congo, with almost 750 suspected cases and 177 suspected deaths, the WHO said.
The outbreak, which experts suspect was circulating under the radar for some time, was caused by the less common Bundibugyo strain of Ebola, for which there are no approved vaccines or treatments.
The WHO is prioritising certain existing treatments to see how effective they might be in combating the strain.
- Situation 'deeply worrisome' -
WHO chief Tedros Adhanom Ghebreyesus said the situation was "especially challenging" as health workers scramble to catch up with the spread of the virus and track down contacts of everyone thought to be infected, in highly insecure areas.
"We know the epidemic in DRC is much larger" than the confirmed cases, he told journalists at the WHO headquarters in Geneva.
The situation in neighbouring Uganda was "stable", with two cases confirmed in people who travelled from DRC and one death, with "intense contact tracing" seemingly having prevented further spread.
While a US national who was working in the DRC has tested positive and been transferred to Germany for care, Tedros said another US national deemed to be a high-risk contact had been transferred to the Czech Republic.
Ebola is a deadly viral disease spread through direct contact with bodily fluids. It can cause severe bleeding and organ failure.
The WHO upgraded its risk assessment level from high to very high for the DR Congo, while keeping the regional risk level at high and the global risk level at low.
The assessment determines the potential impact of a public health threat and the necessary response measures, with WHO advice set to follow.
The WHO's emergency alert and response director Abdi Rahman Mahamud said the assessment looks at the potential risk for human health; the risk of an event spreading; and the capacity available.
"The potential of this virus spreading rapidly is very high, and that changed the whole dynamic," he said.
- Catch-up phase -
Speaking from the field, Anne Ancia, the WHO's representative in the DRC, said the case numbers would keep rising until all the response operations could be put in place.
The virus has been "rampant and silently disseminating for a few weeks already", and "we are sprinting behind" playing catch-up, with the spread "not yet under control", she explained.
When no treatments or vaccines are available, finding contacts and isolating them for 21 days "is the only way that we will be able to disrupt the transmission".
More than 1,400 contacts were being traced in northeastern Ituri province, the outbreak's epicentre, she added.
WHO's Africa regional director Mohamed Yakub Janabi said Ebola had a so-called silent early phase, when symptoms resemble malaria or typhoid, meaning transmission can remain undetected.
Ancia said rising case numbers at this stage was a "good sign" because it showed that surveillance and active discovery of cases was working.
Janabi added that "it often reflects that the response is intensifying, uncovering the true scale of the outbreak".
- Treatment trials planned -
There have only been two previous outbreaks of Bundibugyo, in Uganda in 2007 and DRC in 2012.
With no approved treatments or vaccines for Bundibugyo, WHO chief scientist Sylvie Briand said the UN agency was prioritising all existing tools that might be useful in combating the outbreak.
The WHO research and development branch's technical advisory group on treatments has prioritised two monoclonal antibodies for clinical trials: Regeneron 3479 and Mapp Biopharmaceutical's MBP134.
It also recommended evaluating the oral antiviral obeldesivir in clinical trials as post-exposure prophylaxis for people who are high-risk contacts.
Briand said it looked "promising" as something that might be able to prevent infected contacts from going on to develop disease from that infection.
- No swift vaccine options -
As for vaccines, the Ervebo vaccine works against the Zaire strain of Ebola but there is "very little evidence of cross-protection for Bundibugyo", said Briand.
While a Bundibugyo-specific equivalent has been worked on, there are no doses currently available for clinical trials, and if prioritised, it could take six to nine months to develop.
A.Taylor--AT